Induction cisplatin-based chemotherapy and following radiotherapy in locally advanced basal cell carcinoma of the skin

Acta Oncologica

Volumn 51, Issue 7, 2012, Pages 952-954

  Jaal, Jana ^a,b   Putnik, Kadri ^c  

^a TARTU UNIVERSITY HOSPITAL   (Estonia)

^b UNIVERSITY OF TARTU   (Estonia)

^c North Estonia Medical Centre   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN;

ADVANCED CANCER; AGED; BASAL CELL CARCINOMA; CANCER RADIOTHERAPY; CANCER SIZE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; LETTER; LINEAR ACCELERATOR; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, BASAL CELL; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INDUCTION CHEMOTHERAPY; SCALP; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84866383465     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.670265     Document Type: Letter

References (17)

1. Smith V, Walton S. Treatment of facial Basal cell carcinoma: A review. J Skin Cancer 2011:380371.
2. Mägi M, Aareleid T. Vähihaigestumus ja selle muutused Eestis. Eesti Arst 2009;88:635-40.
3. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: A critical review of the literature and meta-analysis. Arch Dermatol 2000;136:1524-30. (Pubitemid 32009273)
4. Wood G, Gunkel J, Stewart D, Gordon E, Bagheri M, Gharia M, et al. Nonmelanoma skin cancers: Basal cell and squamous cell carcinomas. In: Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna W. Abeloffs clinical oncology, 4th ed. Philadelphia: Churchill Livingstone; 2008. p 1253-70.
5. Bath-Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007:CD003412.
6. Fischbach AJ, Sause WT, Plenk HP. Radiation therapy for skin cancer. West J Med 1980;133:379-82.
7. Pfeiffer P, Hansen O, Rose C. Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature. Eur J Cancer 1990;26:73-7. (Pubitemid 20121854)
8. Moeholt K, Aagaard H, Pfeiffer P, Hansen O. Platinumbased cytotoxic therapy in basal cell carcinoma-a review of the literature. Acta Oncol 1996;35:677-82. (Pubitemid 26366724)
9. Snipes CJ, Sniezek PJ, Walling HW. Basal cell carcinoma responding to systemic 5-fluorouracil. J Am Acad Dermatol 2006;54:1104-6.
10. Guthrie TH, Jr., McElveen LJ, Porubsky ES, Harmon JD. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer 1985;55:1629-32. (Pubitemid 15103904)
11. Luxenberg MN, Guthrie TH, Jr. Chemotherapy of eyelid and peritorbital tumors. Trans Am Ophthalmol Soc 1985; 83:162-80.
12. Morley M, Finger PT, Perlin M, Weiselberg LR, DeBlasio DS. Cis-platinum chemotherapy for ocular basal cell carcinoma. Br J Ophthalmol 1991;75:407-10.
13. Jefford M, Kiffer JD, Somers G, Daniel FJ, Davis ID. Metastatic basal cell carcinoma: Rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg 2004;74:704-5. (Pubitemid 39179568)
14. Luxenberg MN, Guthrie TH, Jr. Chemotherapy of basal cell and squamous cell carcinoma of the eyelids and periorbital tissues. Ophthalmology 1986;93:504-10. (Pubitemid 16111117)
15. Robinson JK. Use of a combination of chemotherapy and radiation therapy in the management of advanced basal cell carcinoma of the head and neck. J Am Acad Dermatol 1987;17:770-4. (Pubitemid 17152074)
16. Guthrie TH, Jr., Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: Results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol 1990;8:342-6. (Pubitemid 20056568)
17. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011; 17:2502-11.